Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease - ...

SHANGHAI, China I June 15, 2025 I Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study ...

HONG KONG, China I June 15, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III ...

INCHEON, South Korea I June 15, 2025 I Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of ...

WILMINGTON, DE, USA I June 15, 2025 I Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and ...

BASEL, Switzerland I June 15, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ ...

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or ...

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In ...

CAMBRIDGE, MA, USA I June 13, 2025 I Regor Therapeutics Group ("Regor"), a global innovator of clinical-stage biotechnology, today announced that it will ...

Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases ...

Partnership further validates Ethris’ novel technology platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity ...

LONDON, UK I June 13, 2025 I AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.